

## PROGRESS REPORT 24.8.2024

We managed to publish the tumor microenvironment study on Nordic post-transplant lymphoproliferative disease (PTLD) cases (N = 75) in *Haematologica* 2023 Nov 1;108(11):3044-3057. doi: 10.3324/haematol.2023.282831, in collaboration with Finnish, Danish and Norwegian colleagues. I had a contribution in study design, collecting the Finnish clinical data, and writing the article together with Suvi-Katri Leivonen. The Scandiatransplant is mentioned in Funding. The main funding was from other sources.

I got very limited study leave in 2022 and 2023. I wish I could have more study leave from my clinical practice. So far, only 21 000 DDK of the grant has been used for my PTLD project.

The fees for the study re-permissions (THL; Finnish Institute for Health and Welfare, and Fimea; Finnish Medicines Agency for human tissue research permission), altogether 7600 DDK, were paid from the grant. My attendance fee for virtual ASH22 congress (American Society of Hematology Annual Meeting in Dec 2022) was paid from the grant, 1920 DDK. Our study group had a poster #2864 over the Nordic PTLD tumor microenvironment results (attached).

My doctoral thesis project is progressing with the third manuscript. The Finnish PTLD cases (N = 215) were analyzed during this spring and the data were shown in European Hematology Association (EHA) Annual Meeting in Madrid in June 2024 (poster P1176, abstract 3871), attached. The salary for the third week of my 3-week study leave in this autumn will be paid from the grant (30.9.-6.10.2024), 11 500 DDK.

The rest of the grant (69 000 DKK) I wish to be able to use for my salary during the spring in 2025, when I hope to get 1,5 – 2 months study leave for writing my thesis. I will make a new report after the third manuscript submission.

Yours sincerely,

Terhi Friman, MD, PhD student, specialist in clinical hematology

Comprehensive Cancer Center, Hematology department,

Helsinki University Hospital and University of Helsinki